{"id":"W4399394481","doi":"10.1200/jco.2024.42.16_suppl.5023","title":"Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Placebo; Oncology; Internal medicine; Cancer; Pathology; Prostate cancer; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001956191,0.000660304,0.0008664519,0.0003483378,0.0001677372,0.0006206399,0.0006324291,0.0005789232,0.002428721],"category_scores_gemma":[0.001471184,0.0003119665,0.0008085573,0.0003240278,0.000416175,0.0004712804,0.0002579717,0.0012591,0.0003484071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006575681,"about_ca_system_score_gemma":0.0007139644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004000691,"about_ca_topic_score_gemma":0.001075555,"domain_scores_codex":[0.9993885,0.0002970947,0.00003242385,0.0001148096,0.0001088017,0.00005844934],"domain_scores_gemma":[0.998897,0.0002763456,0.0004010168,0.00006999321,0.00008631649,0.0002692532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6499054,0.023766,0.1129727,0.001126937,0.002574168,0.0001806814,0.0002002365,0.003649496,0.06594557,0.0002915597,0.002564768,0.1368224],"study_design_scores_gemma":[0.1739183,0.5467494,0.2341737,0.00008784778,0.003255951,0.0007850443,0.0001193026,0.007742056,0.02851214,0.0005202553,0.004025731,0.000110331],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951887,0.001938185,0.0005433154,0.0001263643,0.00003402512,0.0006829549,0.0006552038,0.00003867579,0.0007925211],"genre_scores_gemma":[0.9969165,0.0003214662,0.0006960298,0.0001653457,0.00004026416,0.0004863872,0.0008005189,0.000006588356,0.0005669086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002428721,"threshold_uncertainty_score":0.01034546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1199664458869098,"score_gpt":0.4629382967058643,"score_spread":0.3429718508189545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}